tbuckley/cabot-search huggingface dataset:
Thromboembolism incidence in patients with gastrointestinal tract cancer receiving chemotherapy: A single-institutional retrospective cohort analysis.
Authors: Ayane Oba, Michio Nakamura, Taichi Murai, Chika Matsuda, Kazufumi Itaya, Yuta Koike, Ayana Endo, Yoko Tsukuda, Yuji Ono, Takahiko Kudo, Atsushi Nagasaka, Shuji Nishikawa
Journal: Journal of Clinical Oncology (2016)

541 Background: Although cancer and its treatments are well-recognized risk factors for thromboembolism (TE), such as venous and pulmonary TE, there are very few data of the incidence of cancer associated TE in the Asian population. So we conducted a retrospective cohort study to investigate the TE incidence of gastrointestinal tract cancer (GTC) patients (pts) receiving chemotherapy in a Japanese community hospital’s daily practice setting. Methods: All the patients received chemotherapy for GTC in our hospital from January 2008 to May 2015 were identified through medical records review extracted by our hospital data warehouse. We analyzed the incidences of TE by reviewing all the reports of contrast-enhanced computed tomography performed on each patient during chemotherapy and identified the association between several clinicopathological factors and TE incidence using chi-square tests and logistic regression. Results: Five hundred fourteen Japanese GTC pts were analyzed on this study. Patient characteristics were as follows; male/female 317/197, median age 69.1 (range 21.1 - 89.1), Gastric (GC)/Colorectal cancer (CRC) pts 213/301, non-adjuvant (non-Adj)/adjuvant (Adj) setting 314/200, tumor-bearing (TB)/non-TB pts 344/170, multiple primary (MP)/single primary (SP) pts 29/485. The incident rate with TE in GC and CRC pts was 10.3 % (n = 22) and 16.6 % (n = 50), respectively. In relation to the status of malignancy, the incidence of TE was 16.6 % (n = 52) and 10.0 % (n = 20) in non-Adj and Adj setting (p = 0.0367), 16.9 % (n = 59) and 7.9 % (n = 13) in TB and non-TB pts (p = 0.007), 31.0 % (n = 9) and 13.0 % (n = 63) in MP and SP pts (p = 0.007), respectively. Conclusions: We found that there were significantly higher incidences of TE in non-Adj, TB, and MP compared with Adj, non-TB, and SP pts, respectively. Although the ethnic differences of the TE incidence rate between Caucasian and Asian population were reported, the incidence of Asian population received cancer chemotherapy remains unclear yet. So further accumulation of data are necessary to establish a Guideline for Asian to prevent and manage TE occurred during cancer chemotherapy such as ESMO or ASCO guidelines. Clinical trial information: UMIN000018912.
Improved survival time trends for glioblastoma using the SEER 17 population-based registries.
Authors: M. Koshy, J. L. Villano, T. A. Dolecek, A. Howard, S. Chmura, R. R. Weichselbaum, B. J. McCarthy
Journal: Journal of Clinical Oncology (2011)

2013 Background: The EORTC/NCIC 22981/26981 study demonstrated a significant improvement in median overall survival (OS) from 12.1 to 14.6 months in newly diagnosed glioblastoma (GBM) who received concomitant and adjuvant temozolomide to standard post-operative radiotherapy (RT) (Stupp et al.). The current study was performed to determine if those results have translated into an OS benefit in a population-based cohort. Methods: Patients, ages 20 years and older, who had been diagnosed between January 2000 and December 2006 (follow-up through December, 2007) with a GBM in a brain or central nervous system site and who underwent surgical resection and post-operative RT were selected from the Surveillance, Epidemiology and End Results (SEER) 17 registries research database. Patients were grouped into three time periods for comparison: 2000-2001, 2002-2003, and 2005-2006 (which likely represented the group treated after the EORTC/NCIC trial initial presentation in 2004). OS was estimated by the Kaplan-Meier method, and Cox multivariable regression modeling was used to estimate proportional hazard ratios controlling for potential confounders, such as age, gender, race, extent of surgery, and SEER registry. Results: 7,022 patients were selected with a median follow up of 13 months. Of the cohort, 79.3% received a gross total resection. The median and two year OS for the entire cohort for 2000-2006 was 13 months and 20%, respectively. Over the three time periods studied, there was a significant improvement in the median and 2 year OS of 12 months and 14% for 2000-2001, 13 months and 18% for 2002-2003, and 14 months and 25% for 2005-2006 (p < 0.0001). The estimated adjusted hazard ratio showed that patients diagnosed in 2005-2006 had significantly improved OS when compared to patients diagnosed in earlier time periods (HR = 0.651 95% CI: 0.606 -0.699). Conclusions: The median and 2 year OS of 14 months and 25% in 2005-2006 was similar to the median and 2 year OS of 14.6 months and 26% seen in the EORTC/NCIC phase III study. These results are encouraging and suggest that the improved OS associated with the EORTC/NCIC regimen for GBM patients has successfully been translated to population-based settings.
Oncology massage impact on patient with cancer and caregiver self-reported symptoms as part of an integrative oncology program at a comprehensive cancer center.
Authors: Gabriel Lopez, Kathrin Milbury, Amy Spelman, Qi Wei, Pamela A Sumler, Curtiss M Beinhorn, Eduardo Bruera, Lorenzo Cohen
Journal: Journal of Clinical Oncology (2016)

79 Background: Massage as a manual therapy has shown benefit for symptomatic relief in patients with cancer and their caregivers. We explored the impact of a single massage session on self-reported symptoms in an outpatient clinic at a comprehensive cancer center. Methods: Patients and caregivers received oncology massage treatments (30 or 60-min duration) at our Integrative Medicine Center outpatient clinic from Sep 2012-Jan 2015. Participants completed a modified Edmonton Symptom Assessment Scale (ESAS; 0-10 scale, 10 most severe) pre- and post-massage. ESAS individual items and subscales scores of Physical Distress (PHS), Psychological Distress (PSS), and Global Distress (GSD) were analyzed. We used paired t-tests with a Bonferroni correction (i.e., p &lt; .001) to examine pre/post massage self-reported symptoms. Results: Initial massage visits for 164 patients and 39 caregivers were analyzed. Highest symptoms burden (means) at baseline for patients were Sleep 3.93, Fatigue 3.70, and poor sense of Well-Being 3.62; for caregivers Distress 4.14, Sadness 3.43, and Sleep 3.21. Although patients reported significantly more physical symptoms (F = 27.56, P &lt; .0001) compared to caregivers at baseline, groups did not differ in regard to psychological symptom burden (P = .75). Massage therapy was associated with significant improvements in PHS, PSS, and GSD for both patients and caregivers at P &lt; .0001. Including participants with symptom report ≥ 1, massage resulted in a clinically significant improvement (reduction ≥ 1) in pain, fatigue, sleep, distress, dry mouth, sadness, numbness, anxiety, wellbeing for patients; pain, fatigue, distress, sadness, numbness, anxiety, wellbeing for caregivers. Regarding massage duration, there were no significant effects for 30 vs 60-min duration on pre/post ESAS difference scores. Conclusions: A single 30- or 60-minute massage session resulted in acute relief of self-reported symptoms in patients and caregivers. Further study is warranted regarding optimal massage dose and frequency.
Effect of Chinese herbal medicine JDXZO on epidermal growth factor receptor inhibitor (EGFRIs)–related skin toxicity.
Authors: H. Lin, J. Li
Journal: Journal of Clinical Oncology (2011)

TPS243 Background: Epidermal Growth Factor Receptor Inhibitors (EGFRIs) play an important role in cancer therapy. EGFRIs–related skin toxicity is one of the major dose-limiting toxicities, which can impact quality of life (QQL) and may lead to EGFRIs dose modification or interruption. Chinese herbal medicine JDXZF (including Herba dictamni cortex, etc.) is an empirical formula for reducing cutancous toxicities induced by EGFRIs. The preliminary study has shown Chinese herbal medicine JDXZF is effective for relieving pain and helpful for the skin lesion on treating EGFRIs related skin toxicity. JDXZO is an advanced Chinese herbal extract ointment based on JDXZF for easy use and acceptable. No side effect such as allergy or infection related to JDXZO was found. The purpose of the ongoing clinical trial is to evaluate the efficacy and safety of JDXZO external treatment on EGFRIs related skin toxicity. Methods: This study is designed as multi-center, randomized, double-blind, and placebo-controlled. Entry Criteria: Diagnosis of cancer, with skin toxicity grade≥ 1 (NCI-CTCAE version 3.0) after molecular targeted therapy. Age: 18 to 75. Able to participate in study procedures. No history of hand and foot skin diseases. No concurrent other treatment for EGFRIs–related skin toxicity. Patients were assessed before and after treatment, including a physical examination. Evaluation criteria, CR as symptoms disappear completely, PR as grade decreases more than 1 level, total response rate as CR+PR.
Alloreactive Nk Cells to Augment Antileukemia Cytotoxicity with Allogeneic Stem Cell Transplantation for Aml/Mds: A Phase I Study
Authors: Richard Champlin, Dean A. Lee, Marcelo Fernandez-Vina, Gabriela Rondon, Patricia McAdams, Chen Julianne, Muzaffar H. Qazilbash, Partow Kebriaei, Simrit Parmar, Elizabeth J. Shpall, Uday Popat, Amin Alousi, Stefan O. Ciurea, Laurence Cooper, Thall Peter, John McMannis
Journal: Blood (2010)
Outcome of radical cystectomy series in the management of muscle invasive bladder cancer: Liverpool experience.
Authors: Syed A. Hussain, Altaf Qadir Khattak, Philip Cornford, Robin Weston, Pavlo Somov, Richard Jackson
Journal: Journal of Clinical Oncology (2016)

396 Background: Cystectomy has become one of the standard forms of therapy for patients with muscle invasive bladder cancer with long term follow-up data supporting radical surgical management. Methods: Data are collected retrospectively on patients who underwent cystectomy at the Royal Liverpool University Hospital. The aim was to document the overall survival of patients undergoing cystectomy at this centre. Results: Data were collected on 147 patients between September 2007 and June 2013. Median patient age was 66 (IQR: 61, 72) with 33 (23%) females. 107 (73%) patients had muscle invasive TCC, 13 (9%) had recurrent non-muscle invasice disease, 9 (6%) had salvage surgery following radical radiotherapy and 6 (4%) had persistent carcinoma in situ. 28 patients (20%) had hydronephrosis. 34 (23%) patients underwent neo-adjuvant chemotherapy. 2 (1%) patients had Combined synchronous urethrectomy and 5 (3%) had Combined synchronous nephroureterectomy. Post operatively positive lymph nodes were observed in 22 (19%) of surgical specimens and 83 (72%) had persistent muscle invasive disease. Survival rates at 12 and 60 months are 0.92 (0.88, 0.97) and 0.52 (0.39, 0.71) respectively. Multivariate analysis show that post operative T (HR: 3.99 (1.05, 15.18)) and N (HR: 5.40 (2.17, 13.44)) status are both independent predictors of over all survival. Conclusions: Real life data from our centre showed that the patient population and overall survival estimates for patients with muscle invasive bladder cancer treated with radical cystectomy and lymph node dissection are consistent with previous published literature. .
Copy number variations in AR-associated and DNA repair genes from plasma cell-free DNA of metastatic CRPC patients.
Authors: Ratish Gambhira, Elisa M. Ledet, Aryeneesh Dotiwala, Diptasri Mandal, A. Oliver Sartor
Journal: Journal of Clinical Oncology (2016)

281 Background: Cell-free DNA (cfDNA) present in the plasma of advanced cancer patients can reflect tumor related genetic alterations. Recent data suggests copy number variations (CNVs) in AR-associated and DNA repair pathway genes play a potential role in prostate cancer progression. Here, we performed sequencing of cfDNA from 13 mCRPC patients to evaluate its potential in elucidating tumor related genetic variations. The long-term goal of our project is to correlate cfDNA derived genetic alterations with prostate cancer progression and/or therapeutic resistance/responses. Methods: cfDNA was isolated from 13 advanced mCRPC patient plasma samples using the Qiagen circulating nucleic acid kit. 100ng of cfDNA was utilized for library construction; and the libraries were paired-end sequenced on the Illumina HiSeq 2000. The resulting data was analyzed using the GATK best practices bioinformatics pipeline and the visualized using the SNP &amp; Variation Suite v8.x. Results: The bioanalyzer profiles of cfDNA derived from mCRPC patients is highly fragmented with an average fragment size of 306-605bp. Although, several CNVs were found across the genome, we focused analysis on CNVs related to AR associated and DNA repair genes. Our preliminary analysis of cfDNA, despite low sequencing depth, shows full or partial amplifications in AR (13/13), and other genes including FOXA1, NCOR1, NCOR2 and/or PIK3CA (7/13) and NCOR2 (10/13). For DNA repair genes partial/full amplifications were present in BRAC1, BRAC2, ATM, CDK12, MLH1 and/or MSH2 (7/13). Deletions are less reliably detected in the highly fragmented cfDNA. The majority of these CNVs have been reported in the WGS studies from metastatic CRPC tissue derived genomic DNA (cBioPortal). We are currently validating cfDNA genomic alterations by comparing it to germ line DNA derived via qPCR. Conclusions: Our preliminary study indicates that AR and DNA repair related genetic alterations could be found in the cfDNA derived from metastatic CRPC patients. This warrants more detailed examination of these cfDNA genetic alterations for identifying clinically relevant issues in mCRPC patients.
Disability pension among patients with breast cancer: A Norwegian population-based controlled study.
Authors: B. Hauglann, J. Šaltytë Benth, S. D. Fossa, A. A. Dahl
Journal: Journal of Clinical Oncology (2011)

9039 Background: Cancer is sometimes followed by permanently reduced work ability, which in Norway qualifies for disability pension when the reduction is permanently 50% or more. The aim of this study is to examine various aspects about the 13-year risk of receiving disability pension in women with breast cancer compared to that of matched cancer-free controls. Methods: Cases included 1,555 breast cancer patients registered in the Cancer Registry of Norway, diagnosed 1992-96 and aged 45 to 54 years. For each case a randomly sampled age matched control was identified. All women were followed until they received disability pension or were censored due to retirement (67 years), death or 13 year censoring. Hazard ratios for disability pension were estimated using the Cox proportional hazard model, after adjustment for socio-demographic variables at diagnosis. Results: During the observation period 42.4% of cases and 25.8% of controls got disability pension. Compared to controls, adjusted hazard rate for having disability pension was 2.4 times higher for cases (95%CI 2.1–2.7). Low income, low education, older age, being not married, having no children <18 years and living in rural areas at diagnosis were associated with increased hazard rates of disability pension. Compared to stage I cases, hazard ratios for disability pension were 1.3 (95%CI 1.1-1.5), 1.8 (95%CI 1.1-2.9) and 2.9 (95%CI 2.0-4.3) for stage II, III and IV cases, respectively. Cases receiving disability pension shortly after diagnosis (<3 years) had more advanced cancer, compared to cases receiving later disability pension (>3 years) (p<0.001). Among stage I cases 24% had disability pension within 3 years after diagnosis, compared to 40% for stage II and III, and 66% for stage IV cases. Disability pension was provided at a shorter time from diagnosis in patients with lower versus higher educational level (p<0.002). Conclusions: Survivors of breast cancer are at significantly increased and persistent risk of getting disability pension compared to matched controls. The risk increases with more advanced cancer. Time from diagnosis to disability pension is shorter among survivors with low income, low education and more advanced cancer.
Intraoperative electron radiotherapy in early-stage breast cancer: A report on 226 patients.
Authors: Stefano dall'Oglio, Sergio Maluta, Nadia Marciai, Milena Gabbani
Journal: Journal of Clinical Oncology (2012)

143 Background: We report the results of a single-institution phase II trial of accelerated partial breast irradiation (APBI) using a single dose of intraoperative electron radiotherapy (IOERT) in patients with low-risk early-stage breast cancer. Methods: From July 2006 to December 2009, 226 patients suitable for BCT were enrolled in a phase II trial with IOERT as radical treatment immediately after surgical resection. All patients had biopsy-proven cancer. After the surgeon temporarily re-approximated the excision cavity, a dose of 21 Gy using IOERT was delivered to the tumor bed with a margin of 2 cm laterally. Results: No acute reactions were reported after irradiation. Three patients experienced a transient edema. In 7 others a haematoma was observed. No cases of liponecrosis were observed. With a mean follow-up of 49 months (range 31-66 months), only one case of local recurrence has been reported. The observed toxicity was considered acceptable. As to cosmetic results, at 6 months after the end of IORT, 71/226 patients (31.4.%) had a score of 2 for symmetry and contour (asymmetry exhibited by 1/3 or less of volume breast), while 19/226 (8.4%) had a score 3 (asymmetry greater than 1/3 of breast volume). These findings remained unchanged at the following examinations. No breast oedema, discoloration at site or scar prominence were observed. Conclusions: IOERT offers the advantage of an excellent delineation of the tumor bed under visual control and high sparing of normal tissue, including the skin. IOERT delivers a very high biologically dose at the time of the surgery, when residual tumor cells are more rapidly proliferating. IOERT is insensitive to chemotherapy sequencing since all of the radiation is given during the surgery. The absolute recurrence rate of 0.4% and the recurrence rate per year of 0.2% of the present study are very encouraging. APBI using a single dose of IOERT can be delivered safely in women with early, low-risk breast cancer. A longer follow-up is needed to ascertain its efficacy compared to that of the current standard treatment of whole breast irradiation.
The checkpoint for agonist selection precedes conventional selection in human thymus
Authors: Greet Verstichel, David Vermijlen, Liesbet Martens, Glenn Goetgeluk, Margreet Brouwer, Nicolas Thiault, Yasmine Van Caeneghem, Stijn De Munter, Karin Weening, Sarah Bonte, Georges Leclercq, Tom Taghon, Tessa Kerre, Yvan Saeys, Jo Van Dorpe, Hilde Cheroutre, Bart Vandekerckhove
Journal: Science Immunology (2017)

Immature thymocytes are diverted to the agonist selection pathway before selection of conventional T cells.
Reporting on quality indicators in renal cell carcinoma: Proportion of metastatic patients who initially commence on full-dose targeted therapy.
Authors: Lori Wood, Daniel Yick Chin Heng, Jennifer J. Knox, Georg A. Bjarnason, Christian K. Kollmannsberger, Anil Kapoor, Sebastien J. Hotte, Marie Vanhuyse, Piotr Czaykowski, Denis Soulieres, Antonio Finelli, Zhihui Liu
Journal: Journal of Clinical Oncology (2014)

265 Background: Measuring quality of care is required to improve patient outcomes. There are 23 established Quality Indicators in Renal Cell Carcinoma (RCC) (Wood LA et al, JOP 2013) including initiating targeted therapy (TT) at full dose. It is recognized that the dose of TT is important to optimize clinical outcomes. Methods: The Canadian Kidney Cancer Information System (CKCis) is a prospectively maintained database of RCC pts from 14 Canadian academic centers. CKCis data was used to determine the use of TT in metastatic pts, the initial dose in the first line setting, and factors influencing whether pts initiated full dose TT. Descriptive statistics were performed to characterize current practices and a multivariate logistic regression was performed to assess predictors of initiating full dose TT. Results: Between 2006 and 2014, 560 pts received first-line TT and make up the study cohort. 92% received VEGF TT (81% sunitinib; 9% pazopanib; 2% sorafenib) and 8% received mTOR TT (5% everolimus; 3% temsirolimus). All pts receiving mTOR inhibitors received full dose and are excluded from further analysis. Full dose VEGF TT was initiated in 87% on sunitinib, 78% on pazopanib, and 92% on sorafenib. The sunitinib schedule was 4/2 in 81%, 2/1 in 12%, and other in 7%. Pts were less likely to initiate full dose TT if they were older (OR: 1.10, 95% CI 1.06-1.15), female (OR: 2.23, 95% CI 1.09-4.55) or had a worse ECOG PS (2,3,4 vs 0,1) (OR: 2.30, 95% CI 0.95-5.59). Data on initial versus final dose of TT will also be presented. Conclusions: Maximizing exposure to TT is important in metastatic RCC which is why initiating full dose TT was prioritized as a key QI in RCC. In this study, 87% of pts were initiated on full dose VEGF TT in the first line setting, and 100% of pts on mTOR TT which is higher than predicted. Those less likely to start on full dose VEGF TT were older, female and had a lower ECOG PS. The gender discrepancy will be explored in future studies.
The feasibility of comprehensive volume hyperfractionated (HFx) re-irradiation (Re-RT) for recurrent head and neck (H/N) cancer.
Authors: P. Kumar, M. S. Eaton, O. E. Streeter, U. K. Sinha
Journal: Journal of Clinical Oncology (2010)

e16021 Background: A retrospective review of patients with recurrent H/N cancer treated with comprehensive volume Re-RT was conducted. Methods: Between 2003 and 2009, 23 patients underwent Re-RT for recurrent H/N cancer. Sites included the larynx (n=4), oropharynx (n=5), oral cavity (n=8), and other non-naspharynx sites (n=5). Patients underwent comprehensive volume (i.e., CTV, elective bilateral necks and nodal regions) HFx re-RT [at 110-120 cGy/fx BID with ≥6 hour interval to total planned dose of 7,680-7,700 cGy] with no planned treatment breaks using a 3D conformal approach. 87% of the patients had surgery prior to Re-RT. 95% of the patients had either positive margins, ECE, LVSI, or PNI. Four patients were treated with palliative intent. The median dose and interval from the previous RT was 6680cGy (range 5,040-7,200cGy) and 17 months (range 6-228), respectively. Only two patients received concurrent chemotherapy with re-RT. Results: The median Re-RT dose was 7,320cGy (range 3,240cGy-7,700cGy). The median duration of treatment was 49 days, and the median number of break days was 6 (range 0-26). Eighteen (78%) patients experienced a treatment (tx) related break of ≤1 week, ten of which required no tx related interruptions; while 5 patients needed a break of 1 week due to PEG placement (n=3), infection (n=1) and mucositis (n=1). Major acute toxicities consisted of grade 3 mucositis (n=4 patients, 17%) and grade 3 skin desquamation (n=5, 23%). 2 patients died during treatment with no obvious tx related cause of death. No patients were lost to follow-up. The median overall survival after Re-RT is 3 months (range = 0-26 months). One patient is alive and cNED at 26 months while another died cNED at 26 months from a non- cancer related cause. Eight patients died due to metastatic disease and 4 patients chose hospice after completing palliative Re-RT. Only 4 patients who were treated with curative intent experienced local failure (LF). Conclusions: Unlike other published reports and approaches, comprehensive volume HFx Re-RT is feasible and tolerable in the majority of our patients with low LF rates. Comprehensive volume Re-RT should be considered for patients with recurrent H/N cancer. No significant financial relationships to disclose.
Dynamic Changes in Macrophage Polarization Correlate with Progression and Response in CNS Lymphoma: Insights Into the Transcriptome of Lymphoma-Associated M2 Macrophages,
Authors: Cigall Kadoch, Valerie Wong, Lingjing Chen, Anna Bet-Lachin, Ritu Roy, William Hyun, Caroline Behler, Clifford Lowell, James L. Rubenstein
Journal: Blood (2011)